Header image
               
Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram
        Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.        
                  The Prostate.                
                  2018,
                
                              79(4),
                  
                              352-362,
                          
                  ISSN: 0270-4137,
                
                
                              PMID: 30499118,                          
                 
                          
        
      
    